Alnylam Plunges 42% After Ending Development of a Key Medicine

  • More patients died on drug than those on placebo, company says
  • Alnylam says decision doesn’t affect other lead program

Alnylam Pharmaceuticals Inc. plunged in trading before U.S. exchanges opened after ending development of its late-stage experimental drug for a rare disease because of safety concerns.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.